Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies (LS2.005)

Key Points

• This study aims to compare the efficacy and safety of fenebrutinib and teriflunomide in treating relapsing multiple sclerosis.
• Evaluated adults with relapsing multiple sclerosis
• Compared efficacy and safety profiles of fenebrutinib and teriflunomide
• Fenebrutinib demonstrated superior efficacy compared to teriflunomide in reducing relapse rates.
• Safety profiles were comparable between the two treatments, with no significant differences in adverse events.